Get the Stockscreener App
11.32
2.25%
-0.26
After Hours:
11.11
-0.21
-1.86%
Ars Pharmaceuticals Inc stock is traded at $11.32, with a volume of 1.88M.
It is down -2.25% in the last 24 hours and up +7.81% over the past month.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.
See More
Previous Close:
$11.58
Open:
$11.7
24h Volume:
1.88M
Relative Volume:
0.80
Market Cap:
$1.12B
Revenue:
-
Net Income/Loss:
$-44.84M
P/E Ratio:
-24.09
EPS:
-0.47
Net Cash Flow:
$-44.23M
1W Performance:
+9.80%
1M Performance:
+7.81%
6M Performance:
-14.50%
1Y Performance:
-18.62%
1-Day Range:
$11.00
$11.70
1-Week Range:
$10.00
$11.70
52-Week Range:
$9.335
$18.90
Ars Pharmaceuticals Inc Stock (SPRY) Company Profile
Name
Ars Pharmaceuticals Inc
Sector
Industry
Phone
858-771-9307
Address
11682 EL CAMINO REAL, SUITE 120, SAN DIEGO
Compare SPRY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SPRY
Ars Pharmaceuticals Inc
|
11.32 | 1.14B | 0 | -44.84M | -44.23M | -0.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-04-25 | Initiated | Roth Capital | Buy |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Feb-10-25 | Initiated | Oppenheimer | Outperform |
| Aug-20-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-13-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-12-24 | Reiterated | Leerink Partners | Outperform |
| Jul-25-24 | Initiated | Raymond James | Outperform |
| Mar-05-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-20-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Sep-20-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jan-31-23 | Initiated | Wedbush | Outperform |
| Jan-03-23 | Initiated | William Blair | Outperform |
| Dec-13-22 | Initiated | SVB Leerink | Outperform |
View All
Ars Pharmaceuticals Inc Stock (SPRY) Latest News
How to track smart money flows in ARS Pharmaceuticals Inc.Market Trend Summary & Accurate Trade Setup Notifications - newser.com
Epi Spray Maker Urges FDA to Require More Study of Epi Film - Allergic Living
Pattern recognition hints at ARS Pharmaceuticals Inc. upside2025 Price Momentum & Long-Term Safe Return Strategies - newser.com
Firm Helps Secure Favorable Decision from European Patent Office on Behalf of ARS Pharmaceuticals - Wilson Sonsini
ARS Pharmaceuticals' (SPRY) "Sell (D-)" Rating Reiterated at Weiss Ratings - MarketBeat
ARS Pharmaceuticals Hits Day High with 7.55% Surge to $11.11 - Markets Mojo
ARS Pharmaceuticals Receives Favorable Decision from European Patent Office on Patent Related to neffy - MarketScreener
Asthma Market to Evolve Rapidly Over the Next Decade by 2034, - openPR.com
Firm Advises ARS Pharma on Patent Matters Related to Loan Facility Up to $250 Million - Wilson Sonsini
ARS Pharmaceuticals Forms Death Cross, Signaling Bearish Trend Ahead - Markets Mojo
ARS Pharma’s epinephrine nasal spray patent upheld in Europe By Investing.com - Investing.com Australia
ARS Pharma’s epinephrine nasal spray patent upheld in Europe - Investing.com
ARS Pharmaceuticals Receives Favorable Decision from European Patent Office on Patent Related to neffy® (epinephrine nasal spray) - The Manila Times
ARS Pharmaceuticals receives favorable decision from European Patent Office on patent related to neffy (epinephrine nasal spray) - MarketScreener
ARS Pharmaceuticals Receives Favorable Decision from - GlobeNewswire
EP 3678649 Upheld in 30+ Countries: ARS Pharmaceuticals' neffy® patent Secured Through 2039 - Stock Titan
Knights of Columbus Asset Advisors LLC Boosts Stock Position in ARS Pharmaceuticals, Inc. $SPRY - MarketBeat
What drives ARS Pharmaceuticals Inc stock priceEmerging Market Stocks & Your Free Entry to Smart Investing Starts Here - earlytimes.in
ARS Pharmaceuticals Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Is ARS Pharmaceuticals Inc. building a consolidation baseWeekly Market Report & Safe Entry Point Identification - newser.com
Using data tools to time your ARS Pharmaceuticals Inc. exit2025 Investor Takeaways & Technical Buy Zone Confirmation - newser.com
How to use Fibonacci retracement on ARS Pharmaceuticals Inc.M&A Rumor & Real-Time Sentiment Analysis - newser.com
Published on: 2025-10-05 03:09:06 - newser.com
Is ARS Pharmaceuticals Inc. stock a buy before product launchesWeekly Trade Recap & Breakout Confirmation Alerts - newser.com
A Look at ARS Pharmaceuticals’s Valuation Following Major $250M Funding for Neffy Commercial Growth - Sahm
ARS Pharmaceuticals (SPRY) Is Up 5.2% After Securing $250M Term Loan to Accelerate Neffy Launch – Has the Bull Case Changed? - Yahoo Finance
Why ARS Pharmaceuticals (SPRY) Is Up 7.8% After Securing $250M Loan and Japan Approval for neffy - Sahm
William Blair Maintains ARS Pharmaceuticals(SPRY.US) With Buy Rating - 富途牛牛
ARS Pharma secures $250M loan to accelerate Neffy rollout - MSN
William Blair Expects Lower Earnings for ARS Pharmaceuticals - MarketBeat
ARS Pharmaceuticals (NASDAQ:SPRY) Trading Up 6.6%Here's Why - MarketBeat
Epinephrine nasal spray maker ARS sues Aptar alleging device supply monopoly - Reuters
RA Capital Management Funds Expansion of ARS Pharma Commercial Activity - citybiz
RA Capital Management Funds Expansion of ARS Pharma Commercial Activity, Expands Portfolio of Financing Solutions for Innovative Healthcare Companies - WV News
ARS Pharmaceuticals Secures $250 Million Credit Agreement - MSN
ARS Pharma secures $100 million loan to accelerate neffy growth By Investing.com - Investing.com Nigeria
ARS Pharmaceuticals outlines 2025 growth strategy with neffy commercialization and global expansion - MSN
ARS Pharmaceuticals Locks In $250 Million To Grow Neffy - Finimize
ARS Pharma secures $100 million loan to accelerate neffy growth - Investing.com India
ARS Pharmaceuticals Secures Up to $250 Million Loan - GlobeNewswire
ARS Pharmaceuticals Secures Up to $250 Million Loan Facility with RA Capital Management and OMERS Life Sciences to Accelerate U.S. Commercialization of neffy® - Yahoo Finance
ARS Pharmaceuticals, Inc. announced that it expects to receive $250 million in funding - MarketScreener
ARS Pharmaceuticals Hits 52-Week Low at $9.34 Amid Financial Struggles - Markets Mojo
ARS Pharmaceuticals stock maintains Strong Buy rating at Raymond James By Investing.com - Investing.com Canada
ARS Pharmaceuticals stock maintains Strong Buy rating at Raymond James - Investing.com India
Ars Pharmaceuticals Inc Stock (SPRY) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ars Pharmaceuticals Inc Stock (SPRY) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Scott Kathleen D. | Chief Financial Officer |
Aug 21 '25 |
Option Exercise |
1.50 |
12,500 |
18,750 |
22,542 |
| Scott Kathleen D. | Chief Financial Officer |
Aug 21 '25 |
Sale |
15.00 |
12,500 |
187,500 |
10,042 |
| Tanimoto Sarina | CHIEF MEDICAL OFFICER |
Aug 20 '25 |
Sale |
14.09 |
37,656 |
530,626 |
1,247,447 |
| Tanimoto Sarina | CHIEF MEDICAL OFFICER |
Aug 19 '25 |
Sale |
14.03 |
12,344 |
173,130 |
1,285,103 |
5.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):